-
Mashup Score: 34B‐cell maturation antigen‐based therapies post‐talquetamab in relapsed or refractory multiple myeloma - 4 day(s) ago
eJHaem is a Gold open access haematology journal of the British Society for Haematology, publishing practice and research papers applicable to a worldwide readership.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 41
PURPOSE Outcomes for patients with newly diagnosed multiple myeloma (NDMM) are heterogenous, with overall survival (OS) ranging from months to over 10 years. METHODS To decipher and predict the molecular and clinical heterogeneity of NDMM, we assembled a series of 1,933 patients with available clinical, genomic, and therapeutic data. RESULTS Leveraging a comprehensive catalog of genomic drivers, we identified 12 groups, expanding on previous gene expression–based molecular classifications. To build a model predicting individualized risk in NDMM (IRMMa), we integrated clinical, genomic, and treatment variables. To correct for time-dependent variables, including high-dose melphalan followed by autologous stem-cell transplantation (HDM-ASCT), and maintenance therapy, a multi-state model was designed. The IRMMa model accuracy was significantly higher than all comparator prognostic models, with a c-index for OS of 0.726, compared with International Staging System (ISS; 0.61), revised-ISS (0
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 37Targeting GPRC5D in multiple myeloma - 10 day(s) ago
The prognosis of multiple myeloma (MM) continues to improve. Recent progress in therapies, using immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies, ha…
Source: www.tandfonline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Thread by @HadidiSamer on Thread Reader App - 1 month(s) ago
@HadidiSamer: #mmsm How to counsel patients about Cilta Cel using the data from CARTITUDE-4 and FDA ODAC meeting for earlier use With data of Cilta cel and Ide cel, assuming having access to both for a……
Source: threadreaderapp.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Second Primary Malignancies After Commercial CAR T Cell Therapy: Analysis of FDA Adverse Events Reporting System (FAERS) - 1 month(s) ago
Second primary malignancies (SPMs) were reported in 536 out of 12,394 (4.3%) adverse event reports following CAR T cell therapies in the FDA Adverse Event Repor
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 29Smoldering Multiple Myeloma : Taking the narrow over the wide path? - 2 month(s) ago
Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cells condition considered as a pre-malignant entity that may evolve overtime to symptomatic
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 29Smoldering Multiple Myeloma : Taking the narrow over the wide path? - 2 month(s) ago
Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cells condition considered as a pre-malignant entity that may evolve overtime to symptomatic
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5
This study aims to describe the treatment patterns, outcomes, health care utilization and symptom burden of triple class exposed (TCE) relapsed/refrac…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
Emphasizing precise terminology in clinical studies may improve the transparency and accuracy of information presented at oncology conferences.
Source: www.cancernetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems - 2 month(s) ago
Blood Cancer Journal – Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
Check our recent publication: B‐cell maturation antigen‐based therapies post‐talquetamab in relapsed or refractory multiple myeloma #mmsm ➡️https://t.co/nUjPWLFcaL Talquetamab 1st➡️BCMA BsAb or CAR-T ✅Median F/U:9.5 months(range:6–24mo) ✅Median PFS: 5.5 months (range:1–10mo) https://t.co/tqEhUEkw8k